Clinical Trial

Rifabutin Versus Rifampicin for Treatment of Staphylococcal PJI Treated With DAIR

Study acronym: RIFAMAB
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
Rifampicin, is key in the treatment of staphylococcal PJIs. Rifabutin has a better profile of tolerance than rifampicin regarding the risk of interaction with concomitant medications and liver disorders. The hypothesis is that rifabutin may be an alternative antibiotic option as efficient as rifampicin for the treatment of staphylococcal PJIs, with a better safety profile. The investigator aim to demonstrate the non-inferiority of rifabutin as compared with rifampicin prescribed in combination treatment for PJIs.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2020-12-16; most recent amendment 2022-05-09.
Status change: Not Yet Recruiting → Recruiting 2022-05-09
Trial Details
NCT Number NCT04672525
Lead Sponsor Tourcoing Hospital
Conditions Prosthetic Infection
Enrollment 436 participants
Start Date 2021-11-08
Primary Completion 2026-11 (estimated)
Study Completion 2027-06 (estimated)
Updated on ClinicalTrials.gov 2022-05-10